Merck News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Orderbuch			Analysen
Historisch

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Orderbuch

Analysen

Historisch

24.05.12	Gericht spricht Dow Chemical 2,2 Milliarden Dollar zu (dpa-afx)
13.01.09	Merck Statement in Response to the FDA's Update Regarding a Safety Review of SINGULAIR® (montelukast) (Businesswire)
13.01.09	Merck Statement in Response to the FDA's Update Regarding a Safety Review of SINGULAIR® (montelukast) (Businesswire)
03.12.08	Rosetta Biosoftware Releases the Rosetta Elucidator® System Version 3.2 (Businesswire)
21.07.08	Merck Will Hold Second-Quarter 2008 Sales and Earnings Conference Call and Webcast at 5:30 PM (EDT) on July 21 (Businesswire)
14.07.08	TREDAPTIVE(TM) (Nikotinsäure/Laropiprant) erhält EU-Zulassung - neue lipidmodifizierende Therapie zur Behandlung abnormaler LDL-C-, HDL-C- und Triglycerid-Spiegel (Businesswire)
11.07.08	TREDAPTIV(TM) (nicotinic acid /laropiprant) Approved in the European Union: New Lipid-Modifying Therapy to Treat LDL-C, HDL-C and Triglycerides (Businesswire)
25.06.08	CDC Observes Reduction in Rotavirus Disease After the Introduction of ROTATEQ(R), Merck's Rotavirus Vaccine (Businesswire)
07.06.08	New Data Released at Major Diabetes Meeting on Initial Combination Therapy with JANUVIA(TM) (sitagliptin), Merck's Diabetes Medicine, and Metformin through Two Years of Treatment (Businesswire)
27.05.08	Odanacatib, Merck's Investigational Cathepsin K Inhibitor, Reduced Markers of Bone Turnover in Women with Breast Cancer and Bone Metastases (Businesswire)
21.05.08	ACHIEVE Imaging Study Discontinued (Businesswire)
15.05.08	CDC Recommends ZOSTAVAX(R), Merck's Shingles Vaccine, for All Appropriate Adults Aged 60 and Older (Businesswire)
21.04.08	Wall Street-Schluss: Uneinheitlicher Handel, Quartalszahlen im Fokus (Aktiencheck)
21.04.08	Wall Street: Mässige Verluste, Bank of America und Eli Lilly unter Druck, Merck gesucht (Aktiencheck)
30.01.08	Wall Street Update: Zurückhaltung vor Fed-Sitzung, Yahoo! deutlich leichter (Aktiencheck)
24.12.07	ISENTRESS(R) (Raltegravir) von MSD erhält als erster Integrase-Inhibitor die Zulassung der EU-Kommission (Businesswire)
13.12.07	FDA Advisory Panel Recommends Against Approval of Merck's NDA for Non-prescription MEVACOR(R) (lovastatin) 20 mg (Businesswire)
12.12.07	Merck Announces Voluntary Recall of Certain Lots of PEDVAXHIB(R) and COMVAX(R) (Businesswire)
28.11.07	Highlights of Economic and Business Growth in the Tampa Bay Region (PR Newswire)
09.11.07	Seeger Weiss LLP Announces $4.85 Billion Global Resolution of Vioxx-Related Heart Attack and Stroke Claims Against Merck & Co. (Businesswire)
09.11.07	The Lanier Law Firm Announces $4.85 Billion National Vioxx Settlement With Merck & Co. Inc. (PR Newswire)
05.11.07	Merck's Investigational Extended-Release Niacin/Laropiprant (CORDAPTIVE(TM)) Coadministered with Simvastatin Had Significant Additive Effects on LDL-C, HDL-C and Triglycerides in Phase III Study (Businesswire)
05.11.07	Seven Summits Research Releases Comments on INTC, MRK, PCU, MAT, and CAKE (PR Newswire)
21.10.07	Europäischer Ausschuss für Humanarzneimittel (CHMP) legt positives Gutachten über ATRIPLA(R) vor (Efavirenz 600 mg/ Emtricitabin 200 mg/Tenofovir Disoproxil Fumarat 300 mg) (Businesswire)
18.10.07	European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) (PR Newswire)
05.10.07	Interim Results from a New Trial of CANCIDAS(R) (caspofungin acetate) in Pediatric Patients with Documented Fungal Infections (Businesswire)
26.09.07	Merck to Donate Three Million Doses of Gardasil(R), its Cervical Cancer Vaccine, to Support Vaccination Programs in Lowest Income Nations (Businesswire)
28.08.07	Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet (PR Newswire)
01.08.07	Seven Summits Research Releases Alerts on T, MRK, DO, CTSH, and WFMI (PR Newswire)
23.07.07	Wall Street: Freundlicher Start in die Woche, Merck und Schering-Plough treiben an (Aktiencheck)
16.07.07	ROTATEQ(R) and GARDASIL(R) Adopted by All Immunization Projects of the Centers for Disease Control and Prevention's (CDC) Vaccines for Children (VFC) Program (Businesswire)
29.06.07	Merck Names Peter Kellogg as Executive Vice President and Chief Financial Officer (Businesswire)
09.05.07	New England Journal of Medicine Publishes New Data on GARDASIL(R), Merck's Cervical Cancer Vaccine (Businesswire)
30.04.07	Ausblick: Die Märkte am Montag (Aktiencheck)
25.04.07	New Indication for SINGULAIR(R) (montelukast sodium) Approved to Prevent Exercise-induced Bronchoconstriction (Businesswire)
24.04.07	Merck & Co.: CEO Richard T. Clark wird neuer Chairman (Aktiencheck)
02.04.07	Merck & Co erhält US-Zulassung für Janumet (Aktiencheck)
02.04.07	FDA Approves JANUMET(TM) for Type 2 Diabetes, Offering Powerful Glucose Control of a DPP-4 Inhibitor and Metformin in a Single Tablet (Businesswire)
28.03.07	Ausblick: Die Märkte am Mittwoch (Aktiencheck)
27.03.07	Merck Wins Product Liability Case in Madison County, Ill. - Schwaller v. Merck (Businesswire)
26.03.07	Merck and Schering-Plough to Develop Another New Cholesterol Lowering Medicine (Businesswire)
20.02.07	Merck & Co. kündigt Rücktritt von CFO an (Aktiencheck)
13.02.07	Ben-Gurion University of the Negev Deploys Rosetta Biosoftware Systems for a Pilot Study in Bioinformatics (Businesswire)
08.02.07	MEDAL Program Showed Arthritis Patients Taking ARCOXIA(R) (etoricoxib) Experienced Significantly Fewer Upper Gastrointestinal Events Compared to Diclofenac (Businesswire)
30.01.07	Wall Street: Kaum verändert, Procter & Gamble im Blick, UPS und 3M unter Druck (Aktiencheck)
30.01.07	Merck Announces 2006 Financial Results that Demonstrate Solid Revenue Growth (Businesswire)
19.01.07	VIOXX(R) Plaintiffs Failed to Prove Their Cases (Businesswire)
21.12.06	REPEAT/FDA Approves New Indication for INVANZ(R) (ertapenem) for the Prevention of Surgical Site Infections (SSI) following Elective Colorectal Surgery in Adults (Businesswire)
20.12.06	FDA Approves New Indication for INVANZ(R) (ertapenem) for the Prevention of Surgical Site Infections (SSI) following Elective Colorectal Surgery in Adults (Businesswire)
13.12.06	Merck Wins Federal VIOXX(R) Product Liability Case (Businesswire)
05.12.06	New Data Show Significant Reductions in Both Post-Meal and Fasting Blood Sugar Levels with Sitagliptin Phosphate Plus Metformin as Initial Therapy in Patients with Type 2 Diabetes (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

11:05		Johnson & Johnson baut in der Schweiz Stellen ab - Aktie gewinnt dennoch
11:02		Roche-Aktie gewinnt: Poseida-Übernahme bald abgeschlossen
09:28		Starker Wochentag in Zürich: SPI beginnt Mittwochssitzung mit Gewinnen
09:28		Optimismus in Frankfurt: LUS-DAX zum Handelsstart mit grünem Vorzeichen
09:28		Handel in London: FTSE 100 beginnt Mittwochssitzung mit Gewinnen
09:28		Schwacher Handel in Europa: Euro STOXX 50 beginnt die Mittwochssitzung in der Verlustzone
07.01.25		Dienstagshandel in New York: Dow Jones letztendlich in der Verlustzone

11:05

Johnson & Johnson baut in der Schweiz Stellen ab - Aktie gewinnt dennoch

11:02

Roche-Aktie gewinnt: Poseida-Übernahme bald abgeschlossen

09:28

Starker Wochentag in Zürich: SPI beginnt Mittwochssitzung mit Gewinnen

09:28

Optimismus in Frankfurt: LUS-DAX zum Handelsstart mit grünem Vorzeichen

09:28

Handel in London: FTSE 100 beginnt Mittwochssitzung mit Gewinnen

09:28

Schwacher Handel in Europa: Euro STOXX 50 beginnt die Mittwochssitzung in der Verlustzone

07.01.25

Dienstagshandel in New York: Dow Jones letztendlich in der Verlustzone

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Part Grp Hldg	1’318.50	3.94 %	K V
ABB	50.46	1.98 %	K V
Holcim	89.54	1.66 %	K V
Roche Hldg G	268.40	1.51 %	K V
Sika	219.70	1.29 %	K V
Kuehne+Nagel Int	208.50	0.00 %	K V
Geberit	513.40	-0.04 %	K V
Logitech Intl	79.78	-0.13 %	K V
Sonova Hldg	297.20	-0.27 %	K V
Zurich Insur Gr	549.80	-0.36 %	K V

Nachrichten zu Merck Co.

Aktien Top/Flop

Merck Peer Group Nachrichten

Meistgelesene Nachrichten